"In this regard, insulin resistance, localized to skeletal muscle, has been hypothesized to cause atherogenic dyslipidemia and NAFLD by changing the pattern of storage of ingested carbohydrate away from skeletal muscle glycogen synthesis into hepatic de novo lipogenesis, resulting in an increase in plasma triglyceride concentrations, reduction in plasma high-density lipoprotein concentrations and increased liver triglyceride synthesis in healthy, young, lean insulin resistant individuals (3). This hypothesis has important implications for the treatment of hyperlipidemia and NAFLD associated with the metabolic syndrome in that it implicates skeletal muscle insulin resistance as a primary therapeutic target."